Kolumne, ORE

Original-Research: ZEAL Network SE - from NuWays AG Classification of NuWays AG to ZEAL Network SE Company Name: ZEAL Network SE ISIN: DE000ZEAL241 Reason for the research: Update Recommendation: BUY from: 06.03.2024 Target price: 51.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Henry Wendisch Q4 preview: tough comp for lottery, games still small Topic: ZEAL should release final FY'23 figures on March 20th.

06.03.2024 - 09:06:36

Original-Research: ZEAL Network SE (von NuWays AG): BUY


Original-Research: ZEAL Network SE - from NuWays AG

Classification of NuWays AG to ZEAL Network SE

Company Name: ZEAL Network SE
ISIN: DE000ZEAL241

Reason for the research: Update
Recommendation: BUY
from: 06.03.2024
Target price: 51.00
Target price on sight of: 12 Monaten
Last rating change: 
Analyst: Henry Wendisch

Q4 preview: tough comp for lottery, games still small
 
Topic: ZEAL should release final FY'23 figures on March 20th. Here's what
we expect for Q4'23e:
 
Tough comp for lottery: Against a strong Q4'22 (peaking EuroJackpot), total
German lottery spending (on & offline) has declined by 9% yoy in Q4'23 (+3%
yoy for FY'23; Source: DLTB). For ZEAL it should also be hard to exceed its
strong Q4'22, as we expect a slight yoy decline of 3% to EUR 208m in billings
in Q4'23e. On a a FY'23e basis however, solid billings growth of 11% yoy to
EUR 841m (guidance: EUR 800-830m) should be in the cards thanks to 1.15m MAU
(eNuW; +7.5% yoy) and an ABPU of EUR 61.00 (eNuW; +3.2% yoy). With an average
Lottery gross margin of 12.6% (eNuW), FY'23e sales from Lottery should grow
accordingly by of 6% yoy to EUR 106m (Q4: EUR 26.8m, -9% yoy).
 
Next data point of Games roll-out: While the new segment 'Games' showed
strong KPIs in its first quarter after introduction (Q3'23), we expect
further improvements in Q4, as more games were added and lottery players
should have been cross-sold. However, as regulatory approval takes more
time than anticipated, we expect conservative sales of EUR 1.9m (vs. EUR 1.2m
in Q3), based on an slightly increased pay-in for games of EUR 3.9m (vs. EUR
3.3m for Q3'23) and a constant pay-in to billings ratio.
 
Guidance well in reach: We expect ZEAL to exceed its lottery billings
guidance of EUR 800-830m (eNuW: EUR 841m) while the sales (EUR 110-120m; eNuW: EUR
115m) and EBITDA (EUR 30-35m; eNuW: EUR 33.4m) guidance should be reached at
mid-point.
 
Promising FY'24e outlook: While we expect Lottery sales to grow by 12% yoy
to EUR 119m (driven by continuous marketing driven user intake), the Games
business should also have first meaningful sales contribution of EUR 10m,
implying total sales growth of 18% yoy. As ZEAL currently targets existing
lottery players for its Games business, we model no marketing expenses for
Games while EUR 42m should be spent on Lottery for brand awareness & customer
acquisition. However, as user KPIs for Games look attractive (Q3'23 ARPU: EUR
7.67 at Lottery vs. EUR 22.02 at Games), additional EUR 3-8m of marketing
expenses could be spent on Games in return for more user intake during
FY'24e.
 
Against this backdrop, the recent share price weakness should be a buying
opportunity, especially as Q1'24 saw extraordinary strong jackpots already,
indicating a promising start into a strong growth year. Reiterate BUY with
unchanged PT of EUR 51.00, based on DCF.

You can download the research here:
http://www.more-ir.de/d/29071.pdf
For additional information visit our website
www.nuways-ag.com/research.

Contact for questions
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.
Kontakt für Rückfragen
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------transmitted by EQS Group AG.-------------------


The issuer is solely responsible for the content of this research.
The result of this research does not constitute investment advice
or an invitation to conclude certain stock exchange transactions.

@ dpa.de

Weitere Meldungen

Original-Research: Nynomic AG (von Montega AG): Kaufen Original-Research: Nynomic AG - von Montega AG Einstufung von Montega AG zu Nynomic AG Unternehmen: Nynomic AG ISIN: DE000A0MSN11 Anlass der Studie: Update Empfehlung: Kaufen seit: 10.05.2024 Kursziel: 47,00 EUR (zuvor: 48,00 EUR) Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Miguel Lago Mascato Q1: Solider Jahresauftakt - Steigerung der ausgezeichneten H2/23-Performance & M&A-Newsflow erwartet Nynomic hat Mittwoch Q1-Zahlen veröffentlicht, die eine spürbare Steigerung ggü. (Boerse, 10.05.2024 - 16:16) weiterlesen...

Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH)... Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to MPH Health Care AG Company Name: MPH Health Care AG ISIN: DE000A289V03 Reason for the research: Vorläufige Ergebnisse 2023 Recommendation: Kaufen from: 10.05.2024 Target price: EUR81 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. (Boerse, 10.05.2024 - 12:41) weiterlesen...

Original-Research: Knaus Tabbert AG (von First Berlin Equity Research GmbH): ... Original-Research: Knaus Tabbert AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Knaus Tabbert AG Company Name: Knaus Tabbert AG ISIN: DE000A2YN504 Reason for the research: Dreimonatsbericht Recommendation: Kaufen from: 10.05.2024 Target price: EUR86 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG (ISIN: DE000A2YN504) veröffentlicht. (Boerse, 10.05.2024 - 11:46) weiterlesen...

Original-Research: ZEAL Network SE (von NuWays AG): Kaufen Original-Research: ZEAL Network SE - from NuWays AG Classification of NuWays AG to ZEAL Network SE Company Name: ZEAL Network SE ISIN: DE000ZEAL241 Reason for the research: Recommendation: Kaufen from: 10.05.2024 Target price: EUR 53.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Henry Wendisch Staggering Q1 kicks off new growth phase; chg est. (Boerse, 10.05.2024 - 09:07) weiterlesen...

Original-Research: Nynomic AG (von NuWays AG): Kaufen Original-Research: Nynomic AG - from NuWays AG Classification of NuWays AG to Nynomic AG Company Name: Nynomic AG ISIN: DE000A0MSN11 Reason for the research: Update Recommendation: Kaufen from: 10.05.2024 Target price: EUR 52.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Christian Sandherr Solid start into FY24 despite challenging end markets Topic: Nynomic published a solid start into the year with order intake returning to growth for the first time since Q3 2022. (Boerse, 10.05.2024 - 09:06) weiterlesen...

Original-Research: R. STAHL AG (von NuWays AG): Kaufen. STAHL AG - from NuWays AG Classification of NuWays AG to R. Original-Research: R. (Boerse, 10.05.2024 - 09:02) weiterlesen...